Andreas is an expert in discovery research, drug discovery, and disease model engoineering  with extensive corporate leadership experience.

He is also CTO & COO of Aeon Respire, Inc., developing inhaled small molecule therapeutics for obstructive airway disease.

Prior to Aeon Respire and forming epiQ.bio he served as CSO & COO and member of the executive board of Innoplexus AG, leveraging artificial intelligence and machine learning technologies for therapeutics discovery and development.

Prior to Innoplexus he was co-founder and Chief Scientific/Technology Officer of ISAR Bioscience GmbH and built a translational R&D organization dedicated to engineering hiPSC-derived disease models for drug discovery and regenerative medicine that capture the complex biology underlying multifactorial disease.

Prior to ISAR he was executive team member of AMGEN in Regensburg, serving all of Amgen’s small molecule HTS drug discovery programs.

Before Amgen he was Program Director Human Taste Technologies at BRAIN AG investigating fundamental questions in taste cell biology and developing human taste cell technologies to identify novel taste modulators and functional evaluation of food ingredients.

Andreas holds a Diploma degree in Biology from Marburg University and a PhD in Microbiology from Marburg University/Max-Planck Institute for terrestrial microbiology. He was postdoctoral researcher with Robert Tjian at UC Berkeley / Howard Hughes Medical Institute (HHMI) investigating molecular mechanisms of promoter-selective gene regulation and chromatin remodeling before he continued his academic career as Professor in Biochemistry and faculty lecturer at LMU Munich. He continues to teach at TU Darmstadt and University Regensburg and serves as scientific advisor to Biotech to foster operational and organizational leadership enabling a pioneering spirit and culture of innovation.